These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21967444)

  • 1. Vitamin d and stage 5 chronic kidney disease: a new paradigm?
    Heaf JG; Joffe P; Marckmann P
    Semin Dial; 2012; 25(1):50-8. PubMed ID: 21967444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients.
    Dogan E; Erkoc R; Sayarlioglu H; Soyoral Y; Dulger H
    Ren Fail; 2008; 30(4):407-10. PubMed ID: 18569914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
    Joy MS; Karagiannis PC; Peyerl FW
    J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of adynamic bone disease in African-Americans with CKD stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio.
    Fehmi H; Osman Y; Bhat S; Nguyen K; Daramola O; Cantor T; Monier-Faugere MC; Yee J; Malluche HH
    Clin Nephrol; 2009 Mar; 71(3):267-75. PubMed ID: 19281737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ; Slatopolsky E
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease.
    Wolf M; Thadhani R
    Semin Dial; 2005; 18(4):302-6. PubMed ID: 16076353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.
    Raggi P; Chertow GM; Torres PU; Csiky B; Naso A; Nossuli K; Moustafa M; Goodman WG; Lopez N; Downey G; Dehmel B; Floege J;
    Nephrol Dial Transplant; 2011 Apr; 26(4):1327-39. PubMed ID: 21148030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When is Vitamin D contraindicated in dialysis patients?
    Evenepoel P
    Semin Dial; 2009; 22(3):242-4. PubMed ID: 19572999
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prevention and treatment of renal osteodystrophy: present and future].
    Fernández E; Craver L
    Nefrologia; 2006; 26 Suppl 3():19-27. PubMed ID: 17469423
    [No Abstract]   [Full Text] [Related]  

  • 14. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure.
    Cozzolino M; Gallieni M; Brancaccio D; Arcidiacono T; Bianchi G; Vezzoli G
    J Nephrol; 2006; 19(5):566-77. PubMed ID: 17136683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.
    Sprague SM; Coyne D
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):512-8. PubMed ID: 20133492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic indications obtained from short- and medium-term biohumoral changes after parathyroidectomy].
    Sforzini S; Viganò MR; Rosa M; Redaelli B
    Minerva Med; 1985 Mar; 76(9-10):393-6. PubMed ID: 3982696
    [No Abstract]   [Full Text] [Related]  

  • 18. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M; Brancaccio D
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D treatment in chronic kidney disease.
    Andress DL
    Semin Dial; 2005; 18(4):315-21. PubMed ID: 16076355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When is Vitamin D Contraindicated in Dialysis Patients?
    Goodman WG
    Semin Dial; 2009; 22(3):245-7. PubMed ID: 19573000
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.